Treatment Information

Cancer Monthly > Treatment Information

Back

Lung Cancer treatment details. Chemotherapy.

Yonsei University College of Medicine, Seoul, Korea.

Survival:	months	Country:	Korea
Toxiciy Grade:	4	City/State/Province:	Seoul
Treatments:	Chemotherapy	Hospital:	Yonsei University College of Medicine
Drugs:		Journal:	Link
Date:	Jul 2012

Description:

Patients:
This phase II study involved patients with advanced non-small-cell lung cancer with no prior chemotherapy who were divided into four separate treatment groups. Group A had 37 patients with a median age of 59 years; 32 were male. Group B had 36 patients with a median age of 60 years; 35 were male. Group C had 37 patients with a median age of 58 years; 34 were male. Group D had 36 patients with a median age of 56 years; 33 were male.

Treatment:
Patients in group A were treated with a combination of the chemotherapy agents irinotecan and cisplatin.
Patients in group B were treated with a combination of the chemotherapy agents irinotecan and cisplatin, as well as the biologic therapy agent called isosorbide-5-mononitrate (a drug that acts to dilate the blood vessels).
Patients in group C were treated with a combination of the chemotherapy agents irinotecan and capecitabine.
Patients in group D were treated with a combination of the chemotherapy agents irinotecan and capecitabine, as well as the biologic therapy agent called isosorbide-5-mononitrate (a drug that acts to dilate the blood vessels).

Toxicities:
The most severe treatment-related toxicities in group A were of grade 4. Grade 3-4 effects included neutropenia (60% of patients), anemia (27%), and diarrhea (13%). Grade 1-2 alopecia and nausea/vomiting were also experienced by the majority of patients.

The most severe treatment-related toxicities in group B were of grade 4. Grade 3-4 effects included neutropenia (56% of patients), neutropenia with fever (11%), and anemia (11%). Grade 1-2 alopecia and nausea/vomiting were also experienced by the majority of patients.

The most severe treatment-related toxicities in group C were of grade 4. Grade 3-4 effects included neutropenia (27% of patients) and diarrhea (11%). Grade 1-2 alopecia and nausea/vomiting were also experienced by the majority of patients.

The most severe treatment-related toxicities in group D were of grade 4. Grade 3-4 effects included neutropenia (17% of patients) and diarrhea (6%). Grade 1-2 alopecia and nausea/vomiting were also experienced by the majority of patients.

Results:
The median overall survival times for groups A, B, C, and D were 14.5, 13.0, 16.0, and 13.6 months, respectively.

Correspondence: Dr. J. S. Lee; email: [email protected]

Email Physician More Information

Back